Convenient determination of serum HER‐2 status in breast cancer patients using Raman spectroscopy
Journal of Biophotonics · 2024
DOI: 10.1002/jbio.202300287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biophotonics, 2024. Verfasst von Lintao Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer …. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chengdu Science and Technology Bureau Technology Innovation R&D Project, Sichuan Science and Technology Program.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Given the significant therapeutic efficacy of anti‐HER‐2 treatment, the HER‐2 status is a crucial piece of information that must be obtained in breast cancer patients. Currently, as per guidelines, HER‐2 status is typically acquired from breast tissue of patients. However, there is growing interest in obtaining HER‐2 status from serum and other samples due to the convenience and potential for dynamic monitoring. In this study, we have developed a serum Raman spectroscopy technique that allows for the rapid acquisition of HER‐2 status in a convenient manner. The established HER‐2 negative and positive classification model achieved an area under the curve of 0.8334. To further validate the reliability of our method, we replicated the process using immunohistochemistry and in situ hybridization. The results demonstrate that serum Raman spectroscopy, coupled with artificial intelligence algorithms, is an effective technical approach for obtaining HER‐2 status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospita…
- Department of Mammary Gland Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology…
- Department of Pathology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, C…
- Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology o…
- School of Pharmacy, Macau University of Science and Technology, Taipa, Macau, China.
- State Key Laboratory for Quality Research of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau, China.
ORCID-Profile: Lintao Li
Förderung
- Chengdu Science and Technology Bureau Technology Innovation R&D Project
- Sichuan Science and Technology Program
Zitieren
APA
Li, L., Li, J., Wang, X., Lu, S., Ji, J., Yin, G., Luo, H., Ting, W., Xin, Z., & Wang, D. (2024). Convenient determination of serum HER‐2 status in breast cancer patients using Raman spectroscopy. Journal of Biophotonics. https://doi.org/10.1002/jbio.202300287
Vancouver
Li L, Li J, Wang X, Lu S, Ji J, Yin G, et al. Convenient determination of serum HER‐2 status in breast cancer patients using Raman spectroscopy. Journal of Biophotonics. 2024. doi:10.1002/jbio.202300287
BibTeX
@article{Li2024,
author = {Li, Lintao and Li, Junjie and Wang, Xianliang and Lu, Shun and Ji, Juan and Yin, Gang and Luo, Huaichao and Ting, Wang and Xin, Zhang and Wang, Dongsheng},
title = {Convenient determination of serum HER‐2 status in breast cancer patients using Raman spectroscopy},
journal = {Journal of Biophotonics},
year = {2024},
doi = {10.1002/jbio.202300287}
}
EUVIMED